These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16292541)

  • 1. MYH Y165C and G382D mutations in hepatocellular carcinoma and cholangiocarcinoma patients.
    Baudhuin LM; Roberts LR; Enders FT; Swanson RL; Mettler TA; Aderca I; Stadheim LM; Highsmith WE
    J Cancer Res Clin Oncol; 2006 Mar; 132(3):159-62. PubMed ID: 16292541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk.
    Croitoru ME; Cleary SP; Di Nicola N; Manno M; Selander T; Aronson M; Redston M; Cotterchio M; Knight J; Gryfe R; Gallinger S
    J Natl Cancer Inst; 2004 Nov; 96(21):1631-4. PubMed ID: 15523092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYH rs3219476 and rs3219472 polymorphisms and risk of cholangiocarcinoma.
    You SH; Wang X; Huang S; Wang M; Ji GZ; Xia JR; Fan ZN
    Mol Med Rep; 2013 Jan; 7(1):347-51. PubMed ID: 23138270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MutY homolog Y165C and G382D mutations in cholangiocarinoma: No role.
    Wiwanitkit V
    J Cancer Res Ther; 2015; 11(4):1045. PubMed ID: 26881680
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Wang Y; Hong Y; Li M; Long J; Zhao YP; Zhang JX; Li Q; You H; Tong WM; Jia JD; Huang J
    PLoS One; 2013; 8(12):e82426. PubMed ID: 24349281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas.
    Gismondi V; Meta M; Bonelli L; Radice P; Sala P; Bertario L; Viel A; Fornasarig M; Arrigoni A; Gentile M; Ponz de Leon M; Anselmi L; Mareni C; Bruzzi P; Varesco L
    Int J Cancer; 2004 May; 109(5):680-4. PubMed ID: 14999774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of the MYH gene do not substantially contribute to the risk of breast cancer.
    Beiner ME; Zhang WW; Zhang S; Gallinger S; Sun P; Narod SA
    Breast Cancer Res Treat; 2009 Apr; 114(3):575-8. PubMed ID: 18454351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study.
    Balaguer F; Castellví-Bel S; Castells A; Andreu M; Muñoz J; Gisbert JP; Llor X; Jover R; de Cid R; Gonzalo V; Bessa X; Xicola RM; Pons E; Alenda C; Payá A; Piqué JM;
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):379-87. PubMed ID: 17368238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics of hepatobiliary carcinogenesis.
    Nault JC; Zucman-Rossi J
    Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2017 Feb; 70(3):423-434. PubMed ID: 27634656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copy number aberrations in combined hepatocellular carcinoma and cholangiocarcinoma.
    You HL; Weng SW; Li SH; Wei YC; Sheu JJ; Chen CM; Huang WT
    Exp Mol Pathol; 2012 Jun; 92(3):281-6. PubMed ID: 22366251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYH mutations are rare in prostate cancer.
    Shin EJ; Chappell E; Pethe V; Hersey K; van der Kwast T; Fleshner N; Bapat B
    J Cancer Res Clin Oncol; 2007 Jun; 133(6):373-8. PubMed ID: 17219200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.
    Tannapfel A; Sommerer F; Benicke M; Katalinic A; Uhlmann D; Witzigmann H; Hauss J; Wittekind C
    Gut; 2003 May; 52(5):706-12. PubMed ID: 12692057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effects of polymorphisms of DNA-repair protein genes and metabolic enzyme genes on the risk of cholangiocarcinoma.
    Zeng L; You G; Tanaka H; Srivatanakul P; Ohta E; Viwatthanasittiphong C; Matharit M; Chenvidhya D; Jedpiyawongse A; Tanaka M; Fujii T; Sripa B; Ohshima K; Miwa M; Honjo S
    Jpn J Clin Oncol; 2013 Dec; 43(12):1190-4. PubMed ID: 24049014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline MYH mutations in a clinic-based series of Canadian multiple colorectal adenoma patients.
    Croitoru ME; Cleary SP; Berk T; Di Nicola N; Kopolovic I; Bapat B; Gallinger S
    J Surg Oncol; 2007 May; 95(6):499-506. PubMed ID: 17219385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Koo SH; Ihm CH; Kwon KC; Park JW; Kim JM; Kong G
    Cancer Genet Cytogenet; 2001 Oct; 130(1):22-8. PubMed ID: 11672769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of TERT promoter mutations in primary tumors of the liver.
    Quaas A; Oldopp T; Tharun L; Klingenfeld C; Krech T; Sauter G; Grob TJ
    Virchows Arch; 2014 Dec; 465(6):673-7. PubMed ID: 25267585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.
    Wang AQ; Zheng YC; Du J; Zhu CP; Huang HC; Wang SS; Wu LC; Wan XS; Zhang HH; Miao RY; Sang XT; Zhao HT
    World J Gastroenterol; 2016 May; 22(18):4459-65. PubMed ID: 27182157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
    Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.